Asembia Summit

Streamlined hub services, clinical navigators, and data-driven field reimbursement are transforming the rare disease patient journey.

Tommy Bramley explains how real-world evidence is reshaping how specialty pharma demonstrates value — from trial design to payer negotiations and patient outcomes.

Will Shrank, MD, explains the main hurdles to specialty therapy access, and what will impact the market over the next few years.

Jessica Lovett explains the importance of being connected to the broader access ecosystem and how leveraging partnerships that can provide global insight and intelligence.

Tommy Bramley breaks down the benefits of incorporating real world evidence and data early into a product's lifecycle.

Live from Asembia AXS26, Kim Plesnarski shares what a best-in-class reimbursement and support model looks like.

Bill McElnea and Hinal Sharma discuss how the role of a specialty pharmacy will evolve in the next few years.

Live from Asembia AXS26, Austin Russian examines how specialty therapy launches are evolving.

Jennifer Lospinoso shares how cell and gene therapy access models differ from normal specialty medications, and how the market will adapt in the next five years.

Will Shrank, MD, explains how the specialty pharma pipeline could pose access risks in the future.

Miranda Delatore and Megan Wetzel share their outlook on the future of specialty pharmacy.

Jessica Lovett discusses specialty pharma commercialization timelines, and how the Canadian market is different from the US.

Biopharma manufacturers are navigating growing supply chain complexities, including increased demand for cold chain capacity, the need for sustainable shipping solutions, and the pressure to move products from FDA approval to patients as quickly as possible.

Tommy Bramley explains how real-world evidence can be leveraged to benefit patient outcomes in specialty pharma.

Live from Asembia AXS26, Austin Russian explains how access to rare disease treatments can be delayed.

Bill McElnea and Hinal Sharma discuss the evolving role of a specialty pharmacy.

Kieran Daly explains how adherence and proof of use strategies improve commercial outcomes and the patient experience in specialty pharma.

Kim Plesnarski explains what the biggest inefficiencies are in specialty pharma partnerships.

Jennifer Lospinoso explains how cell and gene therapies are reshaping specialty pharmacy commercialization.

Sydni Johnston, Associate Director at Cardinal Health Sonexus™ Access and Patient Support, explains how manufacturers can build more stable and scalable patient support programs by adopting a flexible approach that aligns hub models with specific organizational goals.

As cell and gene therapies move beyond ultra-rare disease indications into broader patient populations, the commercialization infrastructure built around them is due for a fundamental redesign.

CoverMyMeds' Miranda Delatore and Megan Wetzel discuss AI in prior auth and fixing specialty access bottlenecks upstream.

Will Shrank, MD, evaluates opportunities and challenges in specialty pharma over the next few years.

At Asembia AXS26, Dee Chaudhary broke down how shifting US drug pricing policy is tightening payer controls and changing pharmaceutical pricing and forecasting.

Live from Asembia AXS26, Jessica Lovett explains what real world evidence and data matters most in making decisions around specialty medicines.

Avalere Health analysts map the converging pressures reshaping the drug pricing and distribution landscape ahead of November.

TailorMed broadens patient support beyond copay help, adding five modules that link access, affordability and adherence across specialty medications.

Joel Wayment discusses the implications of the growing cell and gene therapy market on pharma supply chains.

Josh Marsh, Vice President and General Manager of Cardinal Health Sonexus™ Access and Patient Support, outlines the recent shift in the patient services industry towards a hybrid hub model for in-house management and outsourced support.

Rob Truckenmiller, CEO of PharmaCord, talks about the company’s role in patient services, trends he sees shaping patient access to healthcare in the U.S., and a recent patient-centric merger.